Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Investors Put Money Into Affymax, Opsona

by Ann M. Thayer
February 23, 2009 | A version of this story appeared in Volume 87, Issue 8

Institutional investors will buy $42 million worth of Affymax stock in a private transaction. The company's first drug to enter the clinic, Hematide, a synthetic-peptide-based erythropoiesis-stimulating agent, is in Phase III trials for treating anemia associated with chronic renal failure. Separately, Ireland's Opsona Therapeutics, which focuses on autoimmune and inflammatory diseases, has raised $23 million from investors that include the Novartis Venture Fund. Opsona has opened a new lab in Switzerland and plans to complete human proof-of-concept studies using small molecules and biopharmaceuticals to modulate the innate immune system.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.